XBiotech Inc. (XBIT) company profile
Close on Nov 13, 2026Market cap $59.76MP/E –Yield –
About XBiotech
Pharmaceutical Preparations, SIC 2834
XBiotech Inc. is a biopharmaceutical company focused on discovering and developing True Human monoclonal antibodies to treat various diseases. These antibodies are sourced from human donors exhibiting natural immune responses rather than through animal engineering methods. The company focuses on developing antibody therapies that neutralize interleukin-1 alpha, a protein involved in inflammatory tissue breakdown, trauma response, and disease processes. Its clinical and research pipeline includes candidates for conditions in oncology, rheumatology, neurology, and infectious diseases such as methicillin-resistant Staphylococcus aureus, shingles, influenza, and Clostridioides difficile.
The company operates an integrated research and manufacturing campus situated on 48 acres in Austin, Texas, where it conducts laboratory research, clinical trial development, and drug substance production. As of December 31, 2025, XBiotech employed 85 full-time personnel across its administrative, research, and manufacturing operations. The company maintains its principal executive offices in Austin, Texas.
Summary of the business section of XBiotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- XBiotech Inc.
- Founded
- 2005
- Headquarters
- Austin, TX
- Address
- 5217 Winnebago Lane 78744
- Phone
- (512) 386-2900
- Website
- xbiotech.com
- Employees
- 85, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- Whitley Penn LLP, Austin, Texas
Stock & identifiers
- Ticker
- XBIT
- Exchange
- Nasdaq
- IPO date
- Apr 16, 2015
- Shares outstanding
- 30M, Aug 13, 2026
- Public float
- $77.05M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1626878
- CUSIP
- 98400H102
- ISIN
- CA98400H1029
- FIGI
- BBG0081S8D39
- Share class FIGI
- BBG0081S8D48
- LEI
- 5299002WACAY28TQAS52
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jan-Paul Simard | Co-Chief Executive Officer | – |
| John Simard | Director | 4,261,690 |
| David Spencer Soffer | Director | – |
| Thomas Martin Kuendig | Director | 300,000 |
| Tevi David Troy | Director | – |
| Craig Evan Rademaker | Director | 170,985 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $30.10M | $27.10M | $384.58K | $-42 | – |
| FY2024 | $6.25M | $6.25M | $471.50K | $2 | – |
| FY2023 | $5.56M | $5.56M | $499.89K | $14 | – |
| FY2022 | $4.67M | $4.67M | $356.75K | $-69 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| John Simard Former President & Chief Executive Officer | $1.25M | $8.53M | $3.00M | $17.35M | $30.13M | +382% |
| Sushma Shivaswamy Interim Chief Executive Officer & Chief Scientific Officer | $468.56K | $90.00K | – | $12.44K | $570.99K | -13% |
| Angela Hu Director of Finance | $200.00K | $40.00K | – | $5.42K | $245.42K | -14% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 16, 2015
- Offer price
- $19.00
- Securities offered
- 4,000,000
- Gross proceeds
- $76.00M
- Exchange
- Nasdaq
- First trading day
- Apr 15, 2015
- First-day close
- $23.25+22.4%
- Lock-up ends (est.)
- Oct 12, 2015
“We are selling 4,000,000 shares of our common stock at the initial public offering price of $19.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 85 total full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 7, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 13, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 30, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 19, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 16, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?